Ecstasy, or MDMA, is typically detectable in urine for one to three days after a single dose when standard workplace drug screens are used. That window can stretch considerably longer, potentially past six days, when laboratories test for specific MDMA breakdown products rather than the parent drug alone. The gap between those two numbers matters more than most people realize, because it depends not just on your body but on which test is being run and what exactly it is looking for.
What Standard Urine Tests Actually Look For
Most workplace and clinical drug screens start with an immunoassay, a quick and relatively cheap test that reacts to a family of structurally similar compounds. MDMA falls into the amphetamine class, so the initial screen is usually an “amphetamines” panel. If that test flags positive, the sample moves to a confirmation step using a more precise technique like gas chromatography-mass spectrometry, which can distinguish MDMA from other amphetamines and rule out false positives.
Under federal workplace testing guidelines (often called the SAMHSA cutoffs), the confirmation threshold for MDMA and its minor metabolite MDA is 250 ng/mL. At that cutoff, urine samples are unlikely to test positive more than about 48 hours after a single dose.1PubMed Central. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans That roughly two-day window is what you will see quoted in most employer drug-testing policies and pre-employment screening guides. It is real, but it is also the most conservative estimate because it only accounts for the parent drug and one metabolite.
The Metabolite That Changes Everything
Your liver breaks MDMA down into several metabolites, and the most abundant one excreted in urine is HMMA sulfate, which accounts for about 13 percent of a standard dose. Unchanged MDMA, by comparison, makes up roughly 8 to 11 percent of what ends up in your urine.2PubMed Central. Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration Because HMMA sticks around in urine much longer than MDMA itself, testing for it dramatically extends the detection window.
In a controlled study where participants received a high dose of MDMA, HMMA was detectable for as long as 157.8 hours, or about six and a half days. The median last detection time for HMMA was roughly 131 hours, compared to about 95 hours for MDMA itself, a difference of over a day and a half in median terms.1PubMed Central. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans When researchers applied a 250 ng/mL cutoff to HMMA on the third day after dosing, the number of positive specimens jumped from about 1.5 percent (testing only MDMA and MDA) to 9 percent. Some specimens remained positive through days five and six with HMMA included.1PubMed Central. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans
Most routine workplace panels do not test for HMMA. But forensic labs, military testing programs, and some clinical settings increasingly do, especially when there is reason to suspect recent MDMA use but the standard screen comes back clean. HMMA sulfate was confirmed to be the metabolite with the longest urinary detection time in a detailed excretion kinetics study, with over 90 percent of it excreted in conjugated form.3Clinical Chemistry. Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration If you are wondering whether a particular test can catch MDMA use from five or six days ago, the answer depends entirely on whether HMMA is part of the testing panel.
Why the Window Varies from Person to Person
The one-to-three-day range for standard tests and the up-to-six-day range for extended metabolite testing are both averages drawn from controlled studies. In practice, several factors push your personal detection window shorter or longer.
Dose is the most straightforward factor. A higher dose produces more drug and more metabolites in your urine, keeping concentrations above the detection cutoff for longer. The controlled study that found detection out to 6.6 days used what the researchers called a “high dose,” while the low-dose arm showed shorter detection times across the board.1PubMed Central. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans Street ecstasy pills and capsules vary widely in MDMA content, so two people who each take “one pill” could be getting very different doses.
Repeated dosing matters more than you might expect. MDMA inhibits the very liver enzyme responsible for breaking it down. When a second dose is taken during the same session, blood levels of MDMA rise disproportionately: one study found that a second dose produced blood concentrations about 77 percent higher in total exposure and 29 percent higher in peak concentration than the first dose alone, well beyond what simple stacking would predict.4PubMed. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics This self-inhibition effect, sometimes called mechanism-based inhibition, means that redosing during a night out does not just add proportionally more drug to your system. It slows your body’s ability to clear what is already there, leading to higher and longer-lasting urinary concentrations.
MDMA’s pharmacokinetics are also nonlinear at a basic level: as the dose goes up, the body’s non-renal clearance slows while urinary clearance stays relatively steady.5PubMed Central. Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans In plain terms, higher doses overload the system’s ability to break the drug down through the liver, so more MDMA is pushed out unchanged into your urine, and the whole process takes longer.
Do Genetics Change the Timeline?
MDMA is primarily broken down by a liver enzyme called CYP2D6, and people carry different genetic versions of this enzyme. Some people are “poor metabolizers” who have reduced CYP2D6 activity, and you might expect these individuals to clear MDMA more slowly, extending the detection window. In practice, the effect is smaller than the theory would suggest.
A controlled study comparing poor metabolizers to normal metabolizers found that poor metabolizers had about 15 percent higher peak MDMA levels and about 50 percent higher levels of the active metabolite MDA. They also experienced drug effects more rapidly. But the overall difference was described as small, because MDMA itself shuts down CYP2D6 as it is being metabolized.6PubMed Central. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals Everyone, regardless of their starting genetic profile, essentially gets pushed toward the same slow-metabolizer status once MDMA is in their system. This “phenocopying” effect means that genetic differences in CYP2D6 have less real-world impact on MDMA clearance than lab experiments would predict.7PubMed Central. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
Other factors that influence general drug clearance, like kidney function, hydration level, body mass, and urine pH, also play a role. Acidic urine tends to increase the excretion of amphetamine-class drugs. None of these factors will take you from a three-day detection window to zero overnight, but they do help explain why two people who take the same dose at the same time can test differently 48 hours later.
False Positives and Why Confirmation Matters
Immunoassay screens are designed for speed and sensitivity, not pinpoint accuracy. They can cross-react with compounds that look structurally similar to amphetamines but have nothing to do with ecstasy. One documented case involved a patient on fenofibrate, a common cholesterol-lowering medication, whose urine repeatedly tested positive for both amphetamines and MDMA on immunoassay. The positive results appeared on multiple occasions across two different screening platforms. When those same samples were run through gas chromatography-mass spectrometry confirmation, every one came back negative for amphetamines and MDMA. After the patient stopped taking fenofibrate, the false positives disappeared.8Therapeutic Drug Monitoring. False-Positive Amphetamine/Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (CEDIA) and Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (DRI) Test Results With Fenofibrate
This is not an isolated quirk. Other medications and supplements have been reported to trigger amphetamine-class false positives on immunoassays, including certain decongestants, antidepressants, and herbal products. The practical takeaway: a positive screening result is not proof of MDMA use. Any legitimate testing program should require confirmation with a more specific method before acting on the result. If you are taking a prescription that you think might cause a false positive, mention it to the testing provider beforehand and request confirmatory testing if the screen comes back flagged.
Can Detox Products or Adulterants Beat the Test?
The internet is full of products claiming to flush drugs from your system or mask them in urine. These fall into two broad categories: things you ingest to “detoxify” your body, and chemicals you add directly to the urine sample. Neither category is as reliable as sellers claim, and both carry real risks.
Drug-testing laboratories routinely check specimen integrity before running the drug panel itself. They measure pH, creatinine, specific gravity, and temperature, and run additional tests for known adulterants like potassium nitrite, glutaraldehyde, and oxidizing agents. An adulterated specimen that fails these checks is treated the same as a refusal to test.9Therapeutic Drug Monitoring. Beating Drug Tests by Ingesting Detoxifying Agents or Adulterating Urine in vitro: Are These Practices Effective? That outcome is typically worse than a positive result, since it implies deliberate tampering.
Some adulterants are harder to detect with routine integrity checks. Products marketed under names like Klear, Whizzies, and Stealth have been shown to evade basic pH and creatinine tests and can mask moderate drug concentrations in laboratory conditions.10American Journal of Clinical Pathology. The Effects of Adulterants and Selected Ingested Compounds on Drugs-of-Abuse Testing in Urine However, the same study noted that many other common adulterants, including eyedrops, household bleach, and various commercial detox drinks, are caught by standard specimen integrity protocols. Labs continuously update their detection methods, so a product that worked against a particular test in 2005 may not fool a 2025 panel.
Drinking large amounts of water before a test (“dilution”) can temporarily lower drug metabolite concentrations in urine. But labs flag dilute specimens based on low creatinine and specific gravity, and a dilute result usually means you have to retest under observed conditions. There is no shortcut that reliably clears MDMA from your urine faster than your body does on its own.
How Oral Fluid Testing Compares
Urine is the most common matrix for workplace drug testing, but oral fluid (saliva) testing has become increasingly popular because samples can be collected on-site with direct observation, making substitution and adulteration harder. The detection windows are somewhat different.
In a controlled study, MDMA was detectable in oral fluid for about 47 hours after a low dose and up to 71 hours after a high dose. MDA, MDMA’s minor metabolite, had a shorter oral fluid window of roughly 23 to 47 hours depending on dose.11PubMed Central. MDMA and Metabolite Disposition in Expectorated Oral Fluid Following Controlled Oral MDMA Administration Those windows are broadly similar to standard urine testing for the parent drug, but oral fluid testing does not currently look for HMMA, so it does not offer the extended six-day detection that metabolite-inclusive urine testing can provide.
Hair testing, though less common, can detect MDMA use over a much longer period, generally up to 90 days. Hair tests are rarely used in routine employment screening but appear in forensic investigations and some court-ordered monitoring programs. Blood testing, on the other hand, has the shortest window, typically less than 24 hours for MDMA, making it most useful in emergency department settings or roadside impairment assessments.
Sample Stability and Delayed Testing
One concern people sometimes have is whether MDMA breaks down in a stored urine sample before the lab gets around to testing it. The short answer is no, not under normal conditions. A stability study found no significant loss of MDMA (or the related compounds MDA and MDEA) in water or urine across any of the storage temperatures tested over a 21-week period.12PubMed. Stability study of the designer drugs “MDA, MDMA and MDEA” in water, serum, whole blood, and urine under various storage temperatures This means that even if your sample sits in a lab freezer for weeks before testing, the MDMA concentration is not going to degrade in any meaningful way. A positive sample stays positive.
This stability also matters for legal and forensic contexts where chain-of-custody timelines can stretch for months. Defense arguments claiming that MDMA degraded in storage are not well supported by the chemistry.
What Street Ecstasy Means for Detection
Everything discussed above is based on controlled studies where participants received measured, pharmaceutical-grade MDMA. Street ecstasy is a different situation. Pills and capsules sold as ecstasy or “molly” can contain widely varying amounts of MDMA, sometimes far more than the doses used in research. They also frequently contain other psychoactive substances, including methamphetamine, cathinones (bath salts), caffeine, or ketamine, depending on the local market and supply chain.
This matters for detection because taking a pill that contains both MDMA and methamphetamine means your urine will test positive for amphetamines through the methamphetamine pathway as well, which has its own detection window (generally three to five days for the parent compound). You might test positive for amphetamines days after the MDMA itself has cleared. Conversely, a pill sold as ecstasy that contains no MDMA at all will not produce a positive MDMA-specific confirmation, though it could trigger the broader amphetamine immunoassay depending on what it does contain.
Drug-checking services, where available, can identify what is actually in a pill before you take it. From a detection standpoint, not knowing what you ingested makes it impossible to predict your testing timeline with any certainty.
Confirmation Testing Methods and Their Sensitivity
When a urine sample moves past the initial immunoassay screen, the confirmation method determines how much MDMA has to be present for a definitive positive result. Gas chromatography-mass spectrometry (GC-MS) is the traditional gold standard. Different laboratory methods achieve different detection limits: one validated method reported limits of detection as low as 2 ng/mL for MDMA, far below the 250 ng/mL SAMHSA confirmation cutoff.13Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. Confirmation of amphetamine, methamphetamine, MDA and MDMA in urine samples using disk solid-phase extraction and gas chromatography-mass spectrometry after immunoassay screening Another method using a different extraction technique reported quantitation limits of 20 ng/mL for MDMA.14Journal of Analytical Toxicology. Rapid Analysis of Amphetamine, Methamphetamine, MDA, and MDMA in Urine Using Solid-Phase Microextraction, Direct On-Fiber Derivatization, and Analysis by GC-MS
The gap between what a lab instrument can detect and what the official cutoff requires is large. A lab could technically see MDMA in your sample at levels 100 times below the reporting threshold. This distinction matters because some testing contexts, particularly forensic or clinical investigations, use lower cutoffs than the standard workplace screen. A forensic toxicologist investigating a death or assault may report findings at the instrument’s limit of detection rather than the SAMHSA threshold, which could extend the effective detection window by a day or more compared to what a workplace test would catch.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has largely overtaken GC-MS in many modern labs because it requires less sample preparation and can identify a wider range of substances in a single run. Both methods are considered definitive for legal and medical purposes.
The Practical Timeline at a Glance
If you are facing a standard employer or probation urine test that follows SAMHSA guidelines and only looks for MDMA and MDA, the realistic detection window after a single moderate dose is about two days. Heavier doses, redosing during a session, or naturally slower metabolism could push that toward three days. If the testing program also screens for HMMA, which is becoming more common in forensic and military settings, detection could extend past five or even six days after a high dose. And if the substance you took also contained methamphetamine or other amphetamines, those compounds bring their own detection timelines into play. The only way to know for certain what test you are facing and what it looks for is to ask or review the testing protocol directly.